Zymeworks Inc.
ZYMEZymeworks Inc. is a publicly held biotechnology company based in Vancouver, British Columbia, that develops protein therapeutics for the treatment of cancer as well as for autoimmune and inflammatory diseases. The products are based upon the company's molecular modeling software for optimizing protein structure. In 2014, Zymeworks raised $44 million across various funding rounds according to PitchBook, placing it among the top 10 HealthTech businesses in the world to raise the most capital that year. In May 2017, Zymeworks held an IPO on the Toronto Stock Exchange, raising $59 million. This was the largest Canadian biotech IPO in more than a decade. By alphabetical order, Zymeworks is the last company on the Toronto Stock Exchange.
Drugs in Pipeline
0
Phase 3 Programs
0
Upcoming Catalysts
1
Next Catalyst
Aug 6, 2026
27dMarket Overview
Stock performance and key metrics
1 upcoming, 0 past
No drugs found in this phase.
Full breakdown — the signals behind the verdict
Frequently asked questions
When is Zymeworks Inc.'s next FDA catalyst?→
Zymeworks Inc.'s (ZYME) next tracked catalyst is a Earnings expected August 6, 2026. See the catalyst timeline on this page for the full schedule of PDUFA dates, trial readouts and FDA events.
How do I track ZYME biotech catalysts?→
Add ZYME to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow Zymeworks Inc.'s live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.